ArticleP & T : a peer-reviewed journal for formulary management2017
Bezlotoxumab (Zinplava) for
Article in P & T : a peer-reviewed journal for formulary management, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Evaluation of the antibacterial activity of the natural product α-mangostin against Clostridioides difficile.PloS one · 2026Article
- Differences in Patient Access to Newly Approved Antibacterial Drugs in EU/EEA Countries.Antibiotics (Basel, Switzerland) · 2024Review
- Fit-for-purpose heterodivalent single-domain antibody for gastrointestinal targeting of toxin B from Clostridium difficile.Protein science : a publication of the Protein Society · 2024Article
- Characteristics of Patients With InitialOpen forum infectious diseases · 2024Article
- Engineered Secretory Immunoglobulin A provides insights on antibody-based effector mechanisms targetingbioRxiv : the preprint server for biology · 2023Article
- Design of 8-mer peptides that block Clostridioides difficile toxin A in intestinal cells.Communications biology · 2023Article
- Novel Biomarkers, IncludingInfection and immunity · 2023Article
- Design of 8-mer Peptides that BlockbioRxiv : the preprint server for biology · 2023Article
- The Role of Bezlotoxumab for the Prevention of RecurrentAntibiotics (Basel, Switzerland) · 2022Review
- Monoclonal Antibodies for Bacterial Pathogens: Mechanisms of Action and Engineering Approaches for Enhanced Effector Functions.Biomedicines · 2022Review
- Review
- Human C. difficile toxin-specific memory B cell repertoires encode poorly neutralizing antibodies.JCI insight · 2020Article
- Immunotherapy against Systemic Fungal Infections Based on Monoclonal Antibodies.Journal of fungi (Basel, Switzerland) · 2020Review
- A Novel, Orally Delivered Antibody Therapy and Its Potential to PreventFrontiers in microbiology · 2020Article
- [Therapeutic regimens using monoclonal antibodies in gastroenterology].Der Internist · 2019Review
- Clostridioides difficile Infection in the Stem Cell Transplant and Hematologic Malignancy Population.Infectious disease clinics of North America · 2019Review
- Hypoalbuminemia as predictor of recurrence of Clostridium difficile infection.Wiener klinische Wochenschrift · 2019Article
- [Treatment of acute and recurrent Clostridium difficile infections : What is new?]Der Internist · 2018Review
- Application of Antibody-Mediated Therapy for Treatment and Prevention ofFrontiers in microbiology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bezlotoxumab (Zinplava) to prevent the recurrence of
Identifiers
29234211PMC5720485What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.